5th May 2026 09:57
(Alliance News) - Biopharma Credit PLC on Tuesday noted that investment firm Archimed will acquire Esperion Therapeutics.
Biopharma Credit, a London-based closed-ended investment company focused on life sciences industry, said the transaction is valued at up to about USD1.1 billion in total equity value on a fully diluted basis, assuming full achievement of some commercial-based milestones.
Biopharma Credit said it alongside BioPharma Credit Investments V Master LP provided committed financing to Archimed of up to USD400 million. Biopharma Credit's allocation of such commitment will be between USD78 million and USD120 million, it said.
Biopharma Credit said Esperion expects the acquisition to close in the third quarter of 2026.
Biopharma Credit shares rose 0.7% to 70.01 pence each on Tuesday morning in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Biopharma Cred.